This review examines the current landscape of radiopharmaceuticals for endometriosis imaging, comparing the specific limitations of conventional metabolic and receptor-based agents with the molecular rationale and emerging evidence supporting the use of FAP inhibitors (FAPI), thereby positioning them as a promising and potentially pivotal tool in this field. This evidence concerns the gene FAP and endometriosis.